Cell and Gene Outsourcing
-
Comparability Considerations For mRNA Product Development
2/28/2024
Given the mRNA-based products' variability and unique challenges, you may need to modify the standard comparability approach. Let’s discuss strategies for any development stage.
-
How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing
2/27/2024
To address today's challenges and other headwinds, pharma/biotech organizations and CMO/CDMO partners need to re-evaluate and improve externalized operating models. Consider further investing in digitalizing collaboration processes as part of operational excellence and digital transformation road map efforts.
-
EMPQ And Validation Support Services
2/21/2024
A growing pharmaceutical/biotech company hired a global consulting firm for a project that required EMPQ services for qualification activities on a newly completed aseptic processing suite.
-
Formula For Pharmaceutical Logistics And Supply Chain Success In 2024
2/21/2024
Join global logistics leaders for an in-depth analysis of the evolving pharmaceutical supply chain, exploring critical issues, emerging trends, and strategies for navigating the complexities of 2024.
-
Boost Drug Development Productivity With Contract Research Services
2/13/2024
Find out how organ-on-a-chip contract research services are enabling the pharmaceutical industry to overcome the largest challenge in drug development—Eroom’s Law.
-
Contract Research Services For Drug Discovery And Development
2/13/2024
Understand and predict human response earlier in the drug development process, and harness the advantages of Organ-on-a-Chip technology without needing to invest in capital equipment or train personnel.
-
Expert Partnership Contract Testing Services
2/13/2024
Learn about our best-in-class, risk-mitigating solutions with technical and regulatory expertise to help you bring life-changing drugs to market .
-
Consolidating The Supply Chain For mRNA
2/12/2024
Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.
-
What Does The Catalent Acquisition By Novo Holdings Mean For The Biopharma Industry?
2/12/2024
Novo Holdings, the parent company to Novo Nordisk, announced a deal last week to acquire Catalent, the global CDMO, at a value of $16.5bn. In the same breath, Novo Holdings announced they will sell three sites directly to Novo Nordisk, implying that the rest of the assets of the company will continue to operate as a stand-alone CDMO. This article unpacks the acquisition, discussing questions such as “what does it mean for customers?” and “does this deal reshape the CDMO market?”
-
Adopting Modular, Semi-Automated Approaches To Optimize CGT Development
2/7/2024
There are a number of technology solutions that, when applied to a cell and gene therapy workflow, can streamline development and improve workflow integration.